Vinca alkaloids in the therapeutic management of malignant pleural mesothelioma

Cancer Treatment Reviews

Volumn 41, Issue 10, 2015, Pages 853-858

  Ceresoli, Giovanni Luca ^a   Zucali, Paolo Andrea ^b  

^a Humanitas Gavazzeni Hospital   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Chemotherapy; Malignant pleural mesothelioma; Vinca alkaloids; Vinflunine; Vinorelbine

Indexed keywords

NAVELBINE; TUMOR MARKER; VINCA ALKALOID; VINFLUNINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DEOXYCYTIDINE; GEMCITABINE; OXALIPLATIN; PEMETREXED; PLATINUM COMPLEX; VINBLASTINE;

ARTICLE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; GENETIC ANALYSIS; HUMAN; PHARMACOGENOMICS; PLEURA MESOTHELIOMA; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; ANALOGS AND DERIVATIVES; LUNG NEOPLASMS; MESOTHELIOMA; PLEURAL NEOPLASMS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; DEOXYCYTIDINE; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; ORGANOPLATINUM COMPOUNDS; PEMETREXED; PLEURAL NEOPLASMS; VINBLASTINE; VINCA ALKALOIDS;

EID: 84958780647     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2015.10.006     Document Type: Review

References (61)

1. Delgermaa V, Takahashi K, Park EK, Le GV, Hara T, Sorahan T. Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ 2011;89(716-24). 724A-724C.
2. Zucali PA, De Vincenzo F, Simonelli M, Santoro A. Future developments in the management of malignant pleural mesothelioma. Expert Rev Anticancer Ther 2009;9:453-67.
3. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44.
4. van Meerbeeck 1 JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005;23:6881-9.
5. Scagliotti GV, Shin DM, Kindler HL, Vasconcelles MJ, Keppler U, Manegold C, et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 2003;21:1556-61.
6. Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del Conte G, et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 2006;24:1443-8.
7. Castagneto B, Botta M, Aitini E, Spigno F, Degiovanni D, Alabiso O, et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol 2008;19:370-3.
8. Santoro A, O'Brien ME, Stahel RA, Nackaerts K, Baas P, Karthaus M, et al. Pemetrexed plus cisplatin or pemetrexed plus carbolatin for chemonaive patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol 2008;3:756-63.
9. Ceresoli GL, Zucali PA, Gianoncelli L, Lorenzi E, Santoro A. Second-line treatment for malignant pleural mesothelioma. Cancer Treat Rev 2010;36:24-32.
10. Marinaccio A, Binazzi A, Marzio DD, Scarselli A, Verardo M, Mirabelli D, et al. Pleural malignant mesothelioma epidemic: incidence, modalities of asbestos exposure and occupations involved from the Italian National Register. Int J Cancer 2012;130:2146-54.
11. Ceresoli GL, Grosso F, Zucali PA, Mencoboni M, Pasello G, Ripa C, et al. Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey. Br J Cancer 2014;111:220-6.
12. Zhou 1 XJ, Rahmani R. Preclinical and clinical pharmacology of vinca alkaloids. Drugs 1992;44:1-16.
13. Hill BT, Fiebig HH, Waud WR, et al. Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine, in a panel of human tumour xenografts. Eur J Cancer 1999;35:512-20.
14. Steele JP, Shamash J, Evans MT, Gower NH, Tischkowitz MD, Rudd RM. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 2000;18:3912-7.
15. de Haes JC, van Knippenberg FC, Neijt JP. Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer 1990;62:1034-8.
16. Muers MF, Stephens RJ, Fisher P, Darlison L, Higgs CM, Lowry E, et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 2008;371:1685-94.
17. Middleton GW, Smith IE, O'Brien ME, Norton A, Hickish T, Priest K, et al. Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. Ann Oncol 1998;9:269-73.
18. Sørensen JB, Frank H, Palshof T. Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma. Br J Cancer 2008;99:44-50.
19. De Perrot M, Feld R, Cho BC, Bezjak A, Anraku M, Burkes R, et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol 2009;27:1413-8.
20. Maruyama R, Shoji F, Okamoto T, Miyamoto T, Miyake T, Nakamura T, et al. Triplet chemotherapy with cisplatin, gemcitabin and vinorelbina for malignant pleural mesothelioma. Jpn J Clin Oncol 2005;35:433-8.
21. Sørensen JB, Bech C, Sørensen P, Frank H. Phase II study of carboplatin and vinorelbine as first line treatment in advanced malignant pleural mesothelioma. Abstract SO6-1. Presented at the 10th International Mesothelioma Interest Group (IMIG) conference, August 31 - September 2 2010, Kyoto, Japan.
22. Fennell DA, Steele JPC, Shamash J, Sheaff MT, Evans MT, Goonewardene TI, et al. Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma. Lung Cancer 2005;47:277-81.
23. Talbot DC, Margery J, Dabouis G, Dark G, Taylor H, Boussemart H, et al. Phase II study of vinflunine in malignant pleural mesothelioma. J Clin Oncol 2007;5:4751-6.
24. Manegold C, Symanowski J, Gatzemeier U, Reck M, von Pawel J, Kortsik C, et al. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol 2005;16:923-7.
25. Zucali PA, Simonelli M, Michetti G, Tiseo M, Ceresoli GL, Collovà E, et al. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. Lung Cancer 2012;75:360-7.
26. Stebbing J, Powles T, McPherson K, Shamash J, Wells P, Sheaff MT, et al. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer 2009;63:94-7.
27. Zucali PA, Perrino M, Lorenzi E, Ceresoli GL, De Vincenzo F, Simonelli M, et al. Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Lung Cancer 2014;84:265-70.
28. Zauderer MG, Sima CS, Ginsberg MS, Krug LM. Lack of response to vinorelbine in patients with previously treated malignant pleural mesothelioma (MPM): rationale for placebo-controlled trials in the 2nd-line setting. Abstract IB.7. Presented at the 11th International Mesothelioma Interest Group (IMIG) conference, September 11-14, 2012, Boston, MA, USA.
29. Zauderer MG, Kass SL, Woo K, Sima CS, Ginsberg MS, Krug LM. Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma. Lung Cancer 2014;84:271-4.
30. Sørensen JB, Urbanska E, Langer SW, Aamdal E. Second-line oral vinorelbine following first-line platinum and pemetrexed in malignant pleural mesothelioma. Eur J Clin Med Oncol (EJCMO) 2012;4:6-13.
31. Zucali PA, Ceresoli GL, Garassino I, De Vincenzo F, Cavina R, Campagnoli E, et al. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Cancer 2008;112:1555-61.
32. Toyokawa G, Takenoyama M, Hirai F, Toyozawa R, Inamasu E, Kojo M, et al. Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy. Int J Clin Oncol 2014;19:601-6.
33. Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 1998;16:145-52.
34. Roses AD. Pharmacogenetics in drug discovery and development: a translational perspective. Nat Rev Drug Discov 2008;7:807-17.
35. Dumontet C, Sikic BI. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 1999;17:1061-70.
36. Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB. Mechanisms of Taxol resistance related to microtubules. Oncogene 2003;22:7280-95.
37. Lillo MP, Cañadas O, Dale RE, Acuña AU. Location and properties of the taxol binding center in microtubules: a picosecond laser study with fluorescent taxoids. Biochemistry 2002;41:12436-49.
38. Gan PP, Pasquier E, Kavallaris M. Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer Res 2007;67:9356-63.
39. Sève P, Dumontet C. Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol 2008;9:168-75.
40. Verrills NM, Kavallaris M. Improving the targeting of tubulin-binding agents: lessons from drug resistance studies. Curr Pharm Des 2005;11:1719-33.
41. Sève P, Isaac S, Trédan O, Souquet PJ, Pachéco Y, Pérol M, et al. Expression of class III (beta)-tubulin is predictive of patient outcome in patients with nonsmall cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res 2005;11:5481-6.
42. Sève P, Mackey J, Isaac S, Trédan O, Souquet PJ, Pérol M, et al. Class III betatubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 2005;4:2001-7.
43. Zimling ZG, Sørensen JB, Gerds TA, Bech C, Andersen CB, Santoni-Rugiu E. A biomarker profile for predicting efficacy of cisplatin-vinorelbine therapy in malignant pleural mesothelioma. Cancer Chemother Pharmacol 2012;70:743-54.
44. Zimling ZG, Sørensen JB, Gerds TA, Bech C, Andersen CB, Santoni-Rugiu E. Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival. J Thorac Oncol 2012;7:249-56.
45. Mullan PB, Quinn JE, Gilmore PM, McWilliams S, Andrews H, Gervin C, et al. BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene 2001;20:6123-31.
46. Quinn JE, Kennedy RD, Mullan PB, Gilmore PM, Carty M, Johnston PG, et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003;63:6221-8.
47. Tassone P, Tagliaferri P, Perricelli A, Blotta S, Quaresima B, Martelli ML, et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 2003;88:1285-91.
48. Kennedy RD, Quinn JE, Johnston PG, Harkin DP. BRCA1: mechanisms of inactivation and implications for management of patients. Lancet 2002;360:1007-14.
49. Papadaki C, Tsaroucha E, Kaklamanis L, Lagoudaki E, Trypaki M, Tryfonidis K, et al. Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer. Br J Cancer 2011;104:316-23.
50. Taron M, Rosell R, Felip E, Mendez P, Souglakos J, Ronco MS, et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 2004;13:2443-9.
51. Busacca S, Sheaff M, Arthur K, Gray SG, O'Byrne KJ, Richard DJ, et al. BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma. J Pathol 2012;227:200-8.
52. (NCT02139904).
53. Poole AM, Logan DT, Sjöberg BM. The evolution of the ribonucleotide reductases: much ado about oxygen. J Mol Evol 2002;55:180-96.
54. Bepler G, Kusmartseva I, Sharma S, Gautam A, Cantor A, Sharma A, et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in nonsmall- cell lung cancer. J Clin Oncol 2006;24:4731-7.
55. Vilmar AC, Santoni-Rugiu E, Sorensen JB. Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial. Ann Oncol 2013;24:309-14.
56. Zimling ZG, Santoni-Rugiu E, Bech C, Sørensen JB. An unexpected predictive role of RRM1 in malignant pleural mesothelioma treated with cisplatin and vinorelbine. Abstract IA.6. Presented at the 11th International Mesothelioma Interest Group (IMIG) conference, September 11-14, 2012, Boston, MA, USA.
57. Szulkin A, Otvös R, Hillerdal CO, Celep A, Yousef-Fadhel E, Skribek H, et al. Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions. BMC Cancer 2014;14:709.
58. Ceresoli GL, Zucali PA, De Vincenzo F, Gianoncelli L, Simonelli M, Lorenzi E, et al. Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma. Lung Cancer 2011;72:73-7.
59. Pinto C, Novello S, Torri V, Ardizzoni A, Betta PG, Bertazzi PA, et al. Second Italian consensus conference on malignant pleural mesothelioma: state of the art and recommendations. Cancer Treat Rev 2013;39:328-39.
60. Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, de Vuyst P, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J 2010;35:479-95.
61. .